AD101 / AmyriAD - LARVOL DELTA

AD101 - THE CLINICAL PROFILE OF A NEW, FIRSTIN-CLASS TREATMENT FOR ALZHEIMER’S DISEASE. (CTAD 2022) - "AD101 represents a new first-in-class treatment for improvement of global function and cognition when added on to donepezil, the current standard of care for AD. Deficiencies in function drive the cost of care in AD and these data from controlled clinical trials suggest AD101 could be an important addition to patient management. The overall safety profile is favorable for dosages up to 180 mg daily."

Clinical • Alzheimer's Disease • Atrial Fibrillation • Cardiovascular • CNS Disorders • Epilepsy • Infectious Disease • Nephrology

T-TYPE CALCIUM CHANNEL MODULATOR AD101 IMPROVES COGNITIVE FUNCTION IN ANIMAL MODELS OF MEMORY AND LEARNING IMPAIRMENT AND PROVIDES A RATIONALE FOR THE POTENTIAL CLINICAL USE OF AD101 IN THE SYMPTOMATIC TREATMENT OF ALZHEIMER’S DISEASE. (CTAD 2022) - "Describe combined effects of AD101 administration with available therapies such as cholinesterase inhibitors and memantine...7 days of exposure to methamphetamine-induced significant impairments of recognition memory in the NOR...Administration of the dopamine D1 receptor antagonist, SCH23390 and the NMDA receptor antagonist MK-801 blocked the ameliorating effect of AD101 effect as well... AD101 demonstrated beneficial effects on learning and memory function in animal models of normal aging, impaired learning and memory function and Alzheimer’s Disease."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

EFFECTS OF T-TYPE CALCIUM CHANNEL MODULATOR AD101 ON THE ACCUMULATION OF BETA AMYLOID, TAU AND POLYUBIQUITINATED PROTEINS IN ANIMAL MODELS OF ALZHEIMER’S DISEASE. (CTAD 2022) - "These series of studies demonstrate that there are potential mechanisms of action of AD101 targeting protein processing and degradation in neuronal cells. The reduction of polyubiquitinated proteins could be a result from increased rates of proteasomal degradation. Alongside the known effect of AD101in increasing cholinergic neurotransmission, enhanced removal of nonfunctional proteins known to be associated with AD and other neurodegenerative diseases may contribute to the beneficial treatment effects of AD101 in AD."

Preclinical • Alzheimer's Disease • CNS Disorders • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor • Targeted Protein Degradation • APP • CTSD

AmyriAD to Present Clinical and Preclinical Data at the 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference (PRNewswire) - "AmyriAD Therapeutics...announced that it will present data on their lead candidate AD101 at the 15th Clinical Trials on Alzheimer's Disease Conference (CTAD) on November 29 – December 2 in San Francisco, CA. All abstracts will be published in the Journal of Prevention of Alzheimer's Disease (JPAD)....'During CTAD, we will present clinical and preclinical data that clearly support the advancement of our lead candidate, commented Jan Burmeister, M.D., Medical Director at AmyriAD. The team is now gearing up to launch our Phase 3 clinical trial program in the first half of 2023.'"

Clinical data • New P3 trial • Preclinical • Alzheimer's Disease • CNS Disorders

Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer’s Disease Treatment, AD101 (GlobeNewswire) - “Societal CDMO, Inc…announced that it has been selected by AmyriAD Pharma to provide CDMO services to support the ongoing clinical development of AD101….AmyriAD has successfully completed Phase 2 clinical trials of AD101 and is planning to initiate two Phase 3 studies of the compound. Under terms of the new contract, which is valued at nearly $1.0 million, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101. These activities will include packaging, carding, kitting and labeling AD101, matching placebo and an active comparator compound. Additionally, Societal will be responsible for storing the prepared materials and distributing them to clinical trial sites globally.”

Licensing / partnership • Alzheimer's Disease • CNS Disorders